Primary Neuroendocrine Breast Carcinoma in a 13-Year-Old Girl: Ultrasonography and Pathology Findings

Tchaou, Mazamaesso; Darré, Tchin; Folligan, K; Sabi, K.A.; Sonhaye, Lantam; Boume, Azanledji; Bassowa, Akila; Adani-Ifé, Solange; Napo‐Koura, Gado

doi:10.1155/2017/7915806

Cited by 3 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, neoadjuvant endocrine therapy can be selected for suitable patients (elderly patients, patients with poor cardiopulmonary function who cannot tolerate surgery, patients with large tumors or patients with strong desire to preserve breast, and patients who do not agree to neoadjuvant chemotherapy).Then, since HER-2 of NECB is often low-expressed, there is still a lack of relevant evidence-based research of large samples in the biological targeted therapy of NECB with positive HER-2. A small sample of study [ 9 ] reported that it was effective and consistent with the effect observed in general invasive breast cancer. Therefore, currently the majority of experts support biological targeted therapy for patients of NECB with positive HER-2.…”

Section: Discussionsupporting

confidence: 58%

See 1 more Smart Citation

Efficacy of neoadjuvant endocrine therapy in patients with poorly differentiated neuroendocrine carcinoma of the breast

et al. 2020

View full text Add to dashboard Cite

Rationale: Poorly differentiated neuroendocrine carcinoma of the breast is a rare cancer with poor prognosis. There is no standard treatment for the disease. Neoadjuvant therapies and surgery are considered to be the main treatment when the tumor diameter is greater than 5.0 cm. Neoadjuvant therapies include chemotherapy and endocrine therapy. However, the effect of neoadjuvant endocrine therapy is not clear in the disease. Patient concerns: In August 2014, a 28-year-old premenopausal woman noted a mass that was approximately 3.0 cm∗2.0 cm in size on her right breast with pain. Subsequently, the mass has been always increasing significantly. In August 2015, the mass was approximately 7.0 cm∗5.0 cm in size, accompanied by pain, no nipple retraction and discharge, no orange peel-like skin changes, and no dimples. In addition, she had no salient past history. Diagnoses: Histopathological examinations by a biopsy with a thick needle (hollow needle) and surgical resection confirmed poorly differentiated neuroendocrine carcinoma of the right breast. Interventions: First and remarkably, she underwent 3 months of neoadjuvant endocrine therapy (goserelin once every 28 days, and letrozole 10 mg every day). Then, she underwent surgery - stage I breast reconstruction by using prosthesis. Adjuvant endocrine therapy has been used since the operation. Outcomes: According to response evaluation criteria in solid tumors 1.1, the tumor was shrunk by 78.87% after neoadjuvant endocrine therapy. No salient complications were observed. We have followed her for 48 months, and there are no signs of recurrence and metastasis. Lessons: Poorly differentiated neuroendocrine carcinoma of the breast is rare and has a poor prognosis. Currently, there is no standard treatment for this disease. Studies show estrogen receptor and progesterone receptor of neuroendocrine carcinoma of the breast are often highly expressed. In the case, it can be observed that estrogen receptor and progesterone receptor are highly expressed. Therefore, neoadjuvant endocrine therapy may be considered in neuroendocrine carcinoma of the breast when the mass is large and the patient refuses neoadjuvant chemotherapy. We hope to provide an attractive evidence for neoadjuvant endocrine therapy of neuroendocrine carcinoma of the breast. However, more cases are still being needed for research.

show abstract

Section: Discussionsupporting

confidence: 58%

“…[ 7 , 8 ] However, a study indicated that a patient with this tumor was only 13 years old. [ 9 ] The finding suggests that this type of breast cancer can also occur in young and middle-aged women. In addition, it used to occur in a man.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of neoadjuvant endocrine therapy in patients with poorly differentiated neuroendocrine carcinoma of the breast

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This structure can be assessed using indicators relating to the quality or methodology of the diagnosis. This will allow us to better understand the real impact of mammography screening in developing countries [25] [26].…”

Section: Discussionmentioning

confidence: 99%

Breast Cancer: Knowledge, Attitudes on Risk Factors and Means of Screening by Medical Students from Lomé, Togo

Darré¹,

Tchaou²,

Djiwa³

et al. 2020

ABCR

Self Cite

View full text Add to dashboard Cite

Background: Breast cancer is the leading cause of cancer-related death in women around the world. The objective of this study was to assess knowledge and attitudes about breast cancer screening among students in the Faculty of Health Sciences at the University of Lomé. Methods: This was a prospective descriptive transversal study conducted among students enrolled in the Faculty of Health Sciences (FSS) of the University of Lomé (UL) in the 2019 school year account 2020. The purpose of this study was to assess the knowledge and attitudes of medical students about breast cancer screening. Results: In total, the questionnaire was completed by 934 students, for a response rate of 57.1%. The most frequently mentioned risk factors were the presence of a family history of breast cancer (n = 799, 85.55%) and the use of oral or injectable contraceptives (n = 606, 64.88%). There is a statistically significant link between the participants' knowledge of the self-examination and clinical examination of the breasts and certain socio-demographic characteristics, namely age (OR = 0.2, 95% CI [0.11-0.75], p-value < 0.0001), the level of study (OR = 1.5, 95% CI [0.55-2.46], p-value = 0.0054), the follow-up of a course on breast cancer (OR = 2.63, 95% CI [0.32-4.33], p-value = 0.009) and the effectiveness of an internship in a gynecology-obstetrics department (OR = 0.77, 95% CI [0.49-2.56], p-value < 0.0001). Similarly, there is a statistically significant link between participants' knowledge of mammography and cer-How to cite this paper:

show abstract

“…However, few NECB patients are men ( 12 , 15 , 16 ). In addition, a previous study has reported one 13-year-old NECB patient ( 17 ). Several patients have a history of contralateral or ipsilateral invasive carcinoma of no special type with a tumor size ranging from 0.6 to 18.0 cm (mean: 2.3–3.7 cm), and approximately 40% of NECB has axillary lymph nodal metastasis at diagnosis ( 15 , 16 , 18 , 19 ).…”

Section: Epidemiology and Clinical Featuresmentioning

confidence: 96%

Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives

Sun

Dai

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Primary neuroendocrine carcinoma of the breast (NECB) is characterized with heterogeneity, rarity, and poor differentiation, which is probably an underestimated subtype of breast cancer, including small cell NECs and large cell NECs. The diagnostic criteria for NECB have been constantly updated as the disease changes and the understanding increases. According to the latest WHO Classification, primary neuroendocrine neoplasm (NEN) of the breast consists of well-differentiated neuroendocrine tumors (NET), extremely aggressive neuroendocrine carcinomas (NEC) as well as invasive breast cancers of no special type (IBCs-NST) with neuroendocrine differentiation. The accurate diagnosis of NECB remains a challenge for its low incidence, which needs multi-disciplinary methods. For the rarity of the disease, there is a lack of large samples and prospective clinical research. For these invasive tumors, there are no standardized therapeutic guidelines or norms, and the treatment often refers to nonspecific breast cancer. In addition, the prognosis of such patients remains unknown. In 2003, the World Health Organization (WHO) listed NECB as an independent entity for the first time, while few features of NECB were clarified. In this review, it presents the WHO Classification, clinicopathologic characteristics, diagnosis, treatment, and prognosis of these patients. In addition, it summarizes the latest studies on molecular features of NECB, aiming to provide new therapeutic perspectives for the disease.

show abstract

Primary Neuroendocrine Breast Carcinoma in a 13-Year-Old Girl: Ultrasonography and Pathology Findings

Cited by 3 publications

References 22 publications

Efficacy of neoadjuvant endocrine therapy in patients with poorly differentiated neuroendocrine carcinoma of the breast

Efficacy of neoadjuvant endocrine therapy in patients with poorly differentiated neuroendocrine carcinoma of the breast

Breast Cancer: Knowledge, Attitudes on Risk Factors and Means of Screening by Medical Students from Lomé, Togo

Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives

Contact Info

Product

Resources

About

Primary Neuroendocrine Breast Carcinoma in a 13-Year-Old Girl: Ultrasonography and Pathology Findings

Cited by 3 publications

References 22 publications

Efficacy of neoadjuvant endocrine therapy in patients with poorly differentiated neuroendocrine carcinoma of the breast

Efficacy of neoadjuvant endocrine therapy in patients with poorly differentiated neuroendocrine carcinoma of the breast

Breast Cancer: Knowledge, Attitudes on Risk Factors and Means of Screening by Medical Students from Lom&#233;, Togo

Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives

Contact Info

Product

Resources

About

Breast Cancer: Knowledge, Attitudes on Risk Factors and Means of Screening by Medical Students from Lomé, Togo